What is Mounjaro?
Also: tirzepatide · Zepbound
Tirzepatide — a dual GIP/GLP-1 agonist. Larger weight-loss numbers than semaglutide in head-to-head data.
Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly, FDA-approved for type 2 diabetes in 2022. Unlike semaglutide, tirzepatide is a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The weight-loss-labeled version is Zepbound, approved November 2023. In head-to-head trials, tirzepatide produced larger weight loss than semaglutide.
Quick definition
Tirzepatide is the newest major weight-loss drug. The dual GLP-1/GIP mechanism is theoretically more comprehensive than GLP-1 alone — and the head-to-head data so far supports that on average.
How it actually works
GIP is another gut hormone that, like GLP-1, gets released after eating and helps regulate insulin and appetite. Activating both receptors simultaneously produces a stronger combined effect on satiety and glucose handling than either alone.
The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM, n=2,539) found 72 weeks of tirzepatide at the 15 mg dose produced an average 22.5 percent body weight loss versus 2.4 percent on placebo. That's the largest non-surgical weight-loss result in published medical literature. SURMOUNT-5 (2024) directly compared tirzepatide to semaglutide for weight loss — tirzepatide came out 47 percent better on absolute weight loss (~20 percent versus ~14 percent).
Doses titrate slowly: 2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg weekly over 20 weeks. Side-effect profile is similar to semaglutide — nausea, constipation, occasional vomiting. Cost: roughly $1,000 to $1,300/month without insurance.
Why it matters for weight loss
Tirzepatide currently sets the ceiling for non-surgical weight loss. If semaglutide didn't work for you, or you've plateaued, tirzepatide may. Both are chronic medications — discontinue and most patients regain.
Common misconceptions
The biggest myth: tirzepatide is "just stronger Ozempic." Mechanism is genuinely different (dual receptor) and the head-to-head efficacy difference is real and significant. It's not a marketing rebrand.
The second myth: compounded tirzepatide from online clinics is the same drug. Compounded versions vary in quality and have been subject to FDA enforcement actions. Use a licensed pharmacy.
Related terms
- GLP-1 Agonist · Glucagon-Like Peptide-1 Receptor Agonist A drug class that mimics a gut hormone, slowing digestion and dampening appetite.
- Ozempic Semaglutide branded for type 2 diabetes. The drug behind the celebrity weight-loss headlines.
- Wegovy Semaglutide at the FDA-approved weight-loss dose. Same drug as Ozempic, different branding.
- Metformin A first-line type 2 diabetes drug. Off-label for weight loss — modest, not a fat melter.
- Insulin Sensitivity How responsive your cells are to insulin. High sensitivity = good. Low sensitivity (resistance) = trouble.
Read next on Real Easy Diet
Sources
-
[01]
SURPASS / SURMOUNT trials — NEJM New England Journal of Medicine
-
[02]
Tirzepatide — Mayo Clinic Mayo Clinic
- [03]
A printable plan that refuses to count almonds.
Four-week schedule. Grocery list. Swap rules. No "fat-burning loophole." No app to download. You print it, you stick it on the fridge, you eat real food.
- 4-week schedule
- Grocery PDF
- Swap rules
- No app, no fees